Ítem
Solo Metadatos

Cardiovascular disease in the antiphospholipid syndrome

Mostrar el registro sencillo de la publicación
dc.creatorAmaya-Amaya, Jennyspa
dc.creatorRojas-Villarraga, Adrianaspa
dc.creatorAnaya, Juan-Manuelspa
dc.date.accessioned2020-05-25T23:56:51Z
dc.date.available2020-05-25T23:56:51Z
dc.date.created2014spa
dc.description.abstractThe prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed. © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1177/0961203314540015
dc.identifier.issn09612033
dc.identifier.issn14770962
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22542
dc.language.isoengspa
dc.publisherSAGE Publications Ltdspa
dc.relation.citationEndPage1291
dc.relation.citationIssueNo. 12
dc.relation.citationStartPage1288
dc.relation.citationTitleLupus
dc.relation.citationVolumeVol. 23
dc.relation.ispartofLupus, ISSN:09612033, 14770962, Vol.23, No.12 (2014); pp. 1288-1291spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84908690021&doi=10.1177%2f0961203314540015&partnerID=40&md5=74f7372745aca16b26d2995a5fbfef1bspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordHigh density lipoproteinspa
dc.subject.keywordLupus anticoagulantspa
dc.subject.keywordBeta2 glycoprotein 1spa
dc.subject.keywordAnticoagulant therapyspa
dc.subject.keywordAntiphospholipid syndromespa
dc.subject.keywordBlood vessel injuryspa
dc.subject.keywordCardiovascular diseasespa
dc.subject.keywordCardiovascular riskspa
dc.subject.keywordConference paperspa
dc.subject.keywordCongestive cardiomyopathyspa
dc.subject.keywordEarly diagnosisspa
dc.subject.keywordFollow upspa
dc.subject.keywordHeart infarctionspa
dc.subject.keywordHumanspa
dc.subject.keywordHypertriglyceridemiaspa
dc.subject.keywordLifestyle modificationspa
dc.subject.keywordLung embolismspa
dc.subject.keywordPrevalencespa
dc.subject.keywordPulmonary hypertensionspa
dc.subject.keywordThrombotic thrombocytopenic purpuraspa
dc.subject.keywordAntiphospholipid syndromespa
dc.subject.keywordCardiovascular diseasesspa
dc.subject.keywordComplicationspa
dc.subject.keywordPhysiologyspa
dc.subject.keywordRisk factorspa
dc.subject.keywordAntiphospholipid syndromespa
dc.subject.keywordBeta 2-glycoprotein ispa
dc.subject.keywordCardiovascular diseasesspa
dc.subject.keywordHumansspa
dc.subject.keywordRisk factorsspa
dc.subject.keywordAntiphospholipid syndromespa
dc.subject.keywordCardiovascular diseasespa
dc.subject.keywordNovel risk factorsspa
dc.subject.keywordTraditional risk factorsspa
dc.titleCardiovascular disease in the antiphospholipid syndromespa
dc.typeconferenceObjecteng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaDocumento de conferenciaspa
Archivos
Colecciones
Artículos